Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates

Regenxbio (RGNX) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.12%. A quarter ago, it was expected that this biotechnology company would post earnings of $0.41 per share when it actually produced earnings of $0.12, delivering a surprise of -70.73%.Over the last four quarters, the comp ...